Molecular Biology in Treatment Decision Processes—Neuro-Oncology Edition

Abstract

Computational approaches including machine learning, deep learning, and artificial intelligence are growing in importance in all medical specialties as large data repositories are increasingly being optimised. Radiation oncology as a discipline is at the forefront of large-scale data acquisition and well positioned towards both the production and analysis of large-scale oncologic data with the potential for clinically driven endpoints and advancement of patient outcomes. Neuro-oncology is comprised of malignancies that often carry poor prognosis and significant neurological sequelae. The analysis of radiation therapy mediated treatment and the potential for computationally mediated analyses may lead to more precise therapy by employing large scale data. We analysed the state of the literature pertaining to large scale data, computational analysis, and the advancement of molecular biomarkers in neuro-oncology with emphasis on radiation oncology. We aimed to connect existing and evolving approaches to realistic avenues for clinical implementation focusing on low grade gliomas (LGG), high grade gliomas (HGG), management of the elderly patient with HGG, rare central nervous system tumors, craniospinal irradiation, and re-irradiation to examine how computational analysis and molecular science may synergistically drive advances in personalised radiation therapy (RT) and optimise patient outcomes.

Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma

“…Due to the heterogeneity of LGG and the presence of the brain-blood barrier, treatments such as chemotherapy and immunotherapy are not satisfactory ( 15 , 16 ). Therefore, it is of great clinical importance to find new biomarkers and develop new therapeutic strategies for treating LGG ( 17 , 18 ).…”